Navidea Biopharmaceuticals (NAVB) 10-Q 9 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 01, 2019
Document Information [Line Items]
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000810509
Trading Symbol	navb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		18,059,406
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 5,062,857	$ 3,475,881
Available-for-sale securities	200,188	799,270
Accounts and other receivables	206,863	21,151
Prepaid expenses and other	1,004,890	1,299,454
Total current assets	6,474,798	5,595,756
Property and equipment	1,212,090	1,251,185
Less accumulated depreciation and amortization	1,135,466	1,089,013
Property and equipment, net	76,624	162,172
Right-of-use lease assets	397,783
Less accumulated amortization	60,901
Right-of-use lease assets, net	336,882
License agreements, patents and trademarks	480,404	480,404
Less accumulated amortization	66,744	51,912
License agreements, patents and trademarks, net	413,660	428,492
Other assets	828,431	835,107
Total assets	8,130,395	7,021,527
Current liabilities:
Accounts payable	673,021	424,718
Accrued liabilities and other	2,323,144	2,517,047
Notes payable	80,024	316,074
Lease liabilities, current	250,946
Terminated lease liability, current		120,679
Deferred revenue, current	495,000
Total current liabilities	3,822,135	3,378,518
Lease liabilities	613,753
Terminated lease liability		468,494
Deferred revenue	700,000	700,000
Other liabilities	63,000	64,055
Total liabilities	5,198,888	4,611,067
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at June 30, 2019 and December 31, 2018
Common stock; $.001 par value; 300,000,000 shares authorized; 18,059,406 and 10,019,535 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	209,056	200,391
Additional paid-in capital	343,879,087	338,265,383
Accumulated deficit	(341,825,130)	(336,722,905)
Accumulated other comprehensive gain (loss)	188	(730)
Total Navidea stockholders' equity	2,263,201	1,742,139
Noncontrolling interest	668,306	668,321
Total stockholders’ equity	2,931,507	2,410,460
Total liabilities and stockholders’ equity	$ 8,130,395	$ 7,021,527

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	18,059,406	10,019,535
Common stock, shares outstanding (in shares)	18,059,406	10,019,535

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue from contract with customer		$ 16,000	$ 264,000	$ 30,000	$ 265,000
Grant and other revenue		244,199	277,753	282,673	553,403
Revenues, Total		260,092	542,127	301,716	818,572
Cost of revenue		238	35,392	6,364	35,710
Gross profit		259,854	506,735	295,352	782,862
Operating expenses:
Research and development		1,070,642	1,142,718	1,811,225	2,141,674
Selling, general and administrative		1,861,600	1,789,399	3,590,116	3,565,771
Total operating expenses		2,932,242	2,932,117	5,401,341	5,707,445
Loss from operations	[1]	(2,672,388)	(2,425,382)	(5,105,989)	(4,924,583)
Other (expense) income:
Interest income (expense), net		1,630	(23,547)	11,478	7,840
Loss on extinguishment of debt					(4,265,434)
Other, net		(3,220)	2,828	(4,356)	(1,886)
Total other (expense) income, net	[2]	(1,590)	(20,719)	7,122	(4,259,480)
Loss before income taxes		(2,673,978)	(2,446,101)	(5,098,867)	(9,184,063)
Benefit from (provision for) income taxes		168	10,929	(708)	10,929
Loss from continuing operations		(2,673,810)	(2,435,172)	(5,099,575)	(9,173,134)
Gain (loss) from discontinued operations		632	(1,938)	(2,665)	(1,938)
Gain on sale			43,053		43,053
Net loss		(2,673,178)	(2,394,057)	(5,102,240)	(9,132,019)
Less loss attributable to noncontrolling interest		(3)	(16)	(15)	(25)
Net loss attributable to common stockholders		$ (2,673,175)	$ (2,394,041)	$ (5,102,225)	$ (9,131,994)
Loss per common share (basic and diluted):
Continuing operations (in dollars per share)		$ (0.24)	$ (0.30)	$ (0.48)	$ (1.13)
Discontinued operations (in dollars per share)			0.01		0.01
Attributable to common stockholders (in dollars per share)		$ (0.24)	$ (0.29)	$ (0.48)	$ (1.12)
Weighted average shares outstanding (in shares)		11,096,834	8,135,849	10,560,265	8,124,711
Royalty [Member]
Revenue from contract with customer		$ 5,940	$ 6,665	$ 9,090	$ 7,460
License [Member]
Revenue from contract with customer		$ 9,953	$ 257,709	$ 9,953	$ 257,709
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not currently allocated to our individual reportable segments.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Net loss	$ (2,673,178)	$ (2,429,061)	$ (2,394,057)	$ (6,737,962)	$ (5,102,240)	$ (9,132,019)
Unrealized (loss) gain on available-for-sale securities	(40)	958	508	(176)	918	332
Comprehensive loss	$ (2,673,218)	$ (2,428,103)	$ (2,393,549)	$ (6,738,138)	$ (5,101,322)	$ (9,131,687)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017	8,110,332
Balance at Dec. 31, 2017	$ 162,207	$ 331,128,787	$ (319,908,968)	$ (2,396)	$ 668,700	$ 12,048,330
Issued restricted stock (in shares)	10,000
Issued restricted stock	$ 200					200
Stock compensation expense		137,964				137,964
Net income (loss)			(6,737,953)		(9)	(6,737,962)
Unrealized (loss) gain on available-for-sale securities				(176)		(176)
Total comprehensive loss						(6,738,138)
Issued stock to 401(k) plan (in shares)	4,734
Issued stock to 401(k) plan	$ 95	35,885				35,980
Impact of adoption of ASC Topic 606 at Dec. 31, 2017			(700,000)			(700,000)
Issued stock in payment of employee bonuses (in shares)	22,920
Issued stock in payment of employee bonuses	$ 458	164,563				165,021
Balance (in shares) at Mar. 31, 2018	8,147,986
Balance at Mar. 31, 2018	$ 162,960	331,467,199	(327,346,921)	(2,572)	668,691	4,949,357
Balance (in shares) at Dec. 31, 2017	8,110,332
Balance at Dec. 31, 2017	$ 162,207	331,128,787	(319,908,968)	(2,396)	668,700	12,048,330
Net income (loss)						(9,132,019)
Unrealized (loss) gain on available-for-sale securities						332
Total comprehensive loss						$ (9,131,687)
Issued stock to 401(k) plan (in shares)						4,734
Issued stock to 401(k) plan						$ 36,000
Impact of adoption of ASC Topic 606 at Dec. 31, 2017			(700,000)			$ (700,000)
Issued stock in payment of employee bonuses (in shares)						55,938
Issued stock in payment of employee bonuses						$ 317,000
Balance (in shares) at Jun. 30, 2018	8,181,004
Balance at Jun. 30, 2018	$ 163,620	331,697,603	(329,740,962)	(2,064)	668,675	2,786,872
Balance (in shares) at Mar. 31, 2018	8,147,986
Balance at Mar. 31, 2018	$ 162,960	331,467,199	(327,346,921)	(2,572)	668,691	4,949,357
Stock compensation expense		79,183				79,183
Net income (loss)			(2,394,041)		(16)	(2,394,057)
Unrealized (loss) gain on available-for-sale securities				508		508
Total comprehensive loss						(2,393,549)
Issued stock in payment of employee bonuses (in shares)	33,018
Issued stock in payment of employee bonuses	$ 660	151,221				151,881
Balance (in shares) at Jun. 30, 2018	8,181,004
Balance at Jun. 30, 2018	$ 163,620	331,697,603	(329,740,962)	(2,064)	668,675	2,786,872
Balance (in shares) at Dec. 31, 2018	10,019,535
Balance at Dec. 31, 2018	$ 200,391	338,265,383	(336,722,905)	(730)	668,321	2,410,460
Issued restricted stock (in shares)	15,000
Issued restricted stock	$ 300					300
Issued stock pursuant to Stock Purchase Agreement (in shares)	17,857
Issued stock pursuant to Stock Purchase Agreement	$ 357	49,643				50,000
Stock compensation expense		61,978				61,978
Net income (loss)			(2,429,049)		(12)	(2,429,061)
Unrealized (loss) gain on available-for-sale securities				958		958
Total comprehensive loss						(2,428,103)
Balance (in shares) at Mar. 31, 2019	10,052,392
Balance at Mar. 31, 2019	$ 201,048	338,377,004	(339,151,954)	228	668,309	94,635
Balance (in shares) at Dec. 31, 2018	10,019,535
Balance at Dec. 31, 2018	$ 200,391	338,265,383	(336,722,905)	(730)	668,321	2,410,460
Net income (loss)						(5,102,240)
Unrealized (loss) gain on available-for-sale securities						918
Total comprehensive loss						$ (5,101,322)
Issued stock to 401(k) plan (in shares)						8,128
Issued stock to 401(k) plan						$ 20,000
Balance (in shares) at Jun. 30, 2019	18,059,406
Balance at Jun. 30, 2019	$ 209,056	343,879,087	(341,825,130)	188	668,306	2,931,507
Balance (in shares) at Mar. 31, 2019	10,052,392
Balance at Mar. 31, 2019	$ 201,048	338,377,004	(339,151,954)	228	668,309	94,635
Issued stock pursuant to Stock Purchase Agreement (in shares)	8,000,000
Issued stock pursuant to Stock Purchase Agreement	$ 8,000	5,158,441				5,166,441
Stock compensation expense		66,159				66,159
Net income (loss)			(2,673,176)		(3)	(2,673,178)
Unrealized (loss) gain on available-for-sale securities				(40)		(40)
Total comprehensive loss						(2,673,218)
Rounding adjustments related to reverse stock split (in shares)	(1,114)
Rounding adjustments related to reverse stock split		(3,385)				(3,385)
Issued stock to 401(k) plan (in shares)	8,128
Issued stock to 401(k) plan	$ 8	19,580				19,588
Value of warrants issued in connection with public offering		261,288				261,288
Balance (in shares) at Jun. 30, 2019	18,059,406
Balance at Jun. 30, 2019	$ 209,056	$ 343,879,087	$ (341,825,130)	$ 188	$ 668,306	$ 2,931,507

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (5,102,240)	$ (9,132,019)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	73,505	75,498
Compounded interest on long term debt		84,576
Stock compensation expense	128,137	217,147
Loss on extinguishment of debt		4,265,434
Value of stock issued to employees		316,902
Value of stock issued to 401(k) plan for employer matching contributions	19,588	35,980
Changes in operating assets and liabilities:
Accounts and other receivables	(185,712)	12,573,372
Prepaid expenses and other assets	(35,643)	371,538
Accounts payable	248,303	(401,323)
Accrued and other liabilities	91,593	(112,274)
Deferred revenue	483,976	(5,037)
Net cash (used in) provided by operating activities	(4,278,493)	8,289,794
Cash flows from investing activities:
Proceeds from sales of available-for-sale securities	400,000	200,000
Maturities of available-for-sale securities	200,000	800,000
Proceeds from return (payments for purchases) of equipment	26,875	(3,165)
Net cash provided by investing activities	626,875	996,835
Cash flows from financing activities:
Proceeds from issuance of common stock	6,046,915	200
Payment of common stock issuance costs	(572,271)
Payment of debt-related costs		(7,153,000)
Principal payments on notes payable	(236,050)	(237,862)
Net cash provided by (used in) financing activities	5,238,594	(7,390,662)
Net increase in cash and cash equivalents	1,586,976	1,895,967
Cash and cash equivalents, beginning of period	3,475,881	2,795,006
Cash and cash equivalents, end of period	$ 5,062,857	$ 4,690,973

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: The information presented as of June 30, 2019 and for the three -month and six -month periods ended June 30, 2019 and 2018 is unaudited, but includes all adjustments (which consist only of normal recurring adjustments) that the management of Navidea Biopharmaceuticals, Inc. (“Navidea”, the “Company,” or “we”) believes to be necessary for the fair presentation of results for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The balances as of June 30, 2019 and the results for the interim periods are not necessarily indicative of results to be expected for the year. The consolidated financial statements should be read in conjunction with Navidea’s audited consolidated financial statements for the year ended December 31, 2018, which were included as part of our Annual Report on Form 10 -K. Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiary, Navidea Biopharmaceuticals Limited, and our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. On April 26, 2019, the Company effected a one -for- twenty reverse stock split of its issued and outstanding shares of common stock. As a result of the reverse split, each twenty pre-split shares of common stock outstanding automatically combined into one new share of common stock. The number of outstanding common shares was reduced from approximately 201.0 million to approximately 10.1 million shares. The authorized number of shares of common stock was not reduced and remains at 300.0 million. The par value of the Company’s common stock remains unchanged at $0.001 per share after the reverse split. Our consolidated balance sheets, statements of operations, statements of stockholders’ equity, and accompanying notes to the financial statements have been restated, as required, for all periods presented to reflect the reverse stock split as if it had occurred on January 1, 2018. Our consolidated statements of cash flows were not impacted by the reverse stock split. b. Financial Instruments and Fair Value: The following methods and assumptions were used to estimate the fair value of each class of financial instruments: ( 1 ) Cash and cash equivalents , available-for-sale securities, accounts and other receivables, and accounts payable: The carrying amounts approximate fair value because of the short maturity of these instruments. ( 2 ) Notes payable: The carrying value of our debt at June 30, 2019 and December 31, 2018 primarily consisted of the face amount of the notes plus accrued interest. At June 30, 2019, the fair value of our notes payable was approximately $80,000, equal to the carrying value of $80,000. At December 31, 2018, the fair value of our notes payable was approximately $316,000, equal to the carrying value of $316,000. See Note 9. ( 3 ) Derivative liabilities: Derivative liabilities are related to certain outstanding warrants which are recorded at fair value. Derivative liabilities totaling $63,000 as of June 30, 2019 and December 31, 2018 were included in other liabilities on the consolidated balance sheets. The assumptions used to calculate fair value as of June 30, 2019 and December 31, 2018 included volatility, a risk-free rate and expected dividends. In addition, we considered non-performance risk and determined that such risk is minimal. Unrealized gains and losses on the derivatives, if any, are classified in other expenses as a change in the fair value of financial instruments in the statements of operations. See Note 4. c. Revenue Recognition: We currently generate revenue primarily from grants to support various product development initiatives. We generally recognize grant revenue when expenses reimbursable under the grants have been paid and payments under the grants become contractually due. We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. d. Recent ly Adopted Accounting Standards : In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016 - 02, Leases (Topic 842 ) . ASU 2016 - 02 requires the recognition of right-of-use lease assets and lease liabilities by lessees for those leases classified as operating leases under previous U.S. GAAP. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. In July 2018, the FASB issued ASU No. 2018 - 10, Codification Improvements to Topic 842, Leases , and ASU No. 2018 - 11, Targeted Improvements to Topic 842, Leases . ASU 2018 - 10 updates Topic 842 in order to clarify narrow aspects of the guidance issued in ASU 2016 - 02, Leases (Topic 842 ) . ASU 2018 - 11 provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity’s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current U.S. GAAP (Topic 840, Leases ). An entity that elects this transition method must provide the required Topic 840 disclosures for all periods that continue to be in accordance with Topic 840. The amendments in ASU 2018 - 10 and ASU 2018 - 11 are effective when ASU 2016 - 02 is effective, for fiscal years beginning after December 15, 2018. The Company adopted ASU 2016 - 02, ASU 2018 - 10 and ASU 2018 - 11 effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. Related to the adoption of these standards, the Company made a short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with an initial term of 12 months or less. The adoption of ASU 2016 - 02 resulted in the recognition of operating lease right-of-use assets and related lease liabilities of approximately $407,000 on the consolidated balance sheet as of January 1, 2019 related to our leases that were previously classified as operating leases, primarily for office space. The adoption of ASU 2016 - 02 did not materially impact our operating results or liquidity. Disclosures related to the amount, timing and uncertainty of cash flows arising from leases are included in Note 10. In June 2018, the FASB issued ASU No. 2018 - 07, Compensation—Stock Compensation (Topic 718 ) – Improvements to Nonemployee Share-Based Payment Accounting . ASU 2018 - 07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. ASU 2018 - 07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, and that Topic 718 does not apply to share-based payments used to effectively provide ( 1 ) financing to the issuer or ( 2 ) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers . ASU 2018 - 07 is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The adoption of ASU 2018 - 07 did not have a significant impact on our consolidated financial statements. In July 2018, the FASB issued ASU No. 2018 - 09, Codification Improvements . ASU 2018 - 09 updates a variety of topics in order to clarify, correct errors, or make minor improvements to the Codification, making it easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. Certain amendments in ASU 2018 - 09 were effective upon issuance, others are effective for annual periods beginning after December 15, 2018 for public business entities, and some have been made to recently issued guidance and will be subject to the effective dates within the relevant guidance. The adoption of ASU 2018 - 09 did not have a significant impact on our consolidated financial statements.

Note 2 - Liquidity

Note 2 - Liquidity	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the Company’s Annual Report on Form 10 $4.1 11. The Company was also engaged in litigation with Platinum-Montaur Life Sciences LLC (“Platinum-Montaur”), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P. (“PPVA”), Platinum Partners Capital Opportunity Fund (“PPCO”), Platinum Partners Liquid Opportunity Master Fund L.P., Platinum Liquid Opportunity Management (NY) LLC, and Montsant Partners LLC (collectively, “Platinum”), in which Platinum-Montaur was seeking damages of approximately $1.9 October 2018, November 2018, September 5, 2019 9 11. In addition, the Company is engaged in litigation with our former President and Chief Executive Officer, Dr. Michael Goldberg. See Notes 7 11. On June 18, 2019, 8,000,000 $0.001 June 13, 2019, $0.75 8,000,000 4,000,000 $0.75 4,000,000 $0.69375 $5,555,000. 2b 3 Tc99m The Company is currently engaged in litigation with CRG, Platinum and Dr. Goldberg. In addition, the Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The recent underwritten public offering provided approximately $5.5 twelve 10

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3 . Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 The Company also has an agreement in place to provide Meilleur Technologies, Inc., (“Meilleur”), a wholly-owned subsidiary of Cerveau Technologies, Inc. (“Cerveau”), worldwide rights to conduct research using NAV4694, NAV4694 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 90 Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight 10 The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. Tc99m not no no The sublicense of NAV4694 Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the three June 30, 2019 2018, $16,000 $264,000, six June 30, 2019 2018, $30,000 $265,000, three six June 30, 2019 2018, not nor The following tables disaggregate the Company’s revenue from contracts with customers for the three six June 30, 2019 2018. T hree Months Ended June 30 , 2019 Diagnostics Royalty revenue: Europe $ 5,940 License revenue: NAV4694 sublicense $ 9,953 T hree Months Ended June 30 , 2018 Diagnostics Royalty revenue: Europe $ 6,665 License revenue: NAV4694 sublicense $ 257,709 Six Months Ended June 30, 2019 Diagnostics Royalty revenue: Europe $ 9,090 License revenue: NAV4694 sublicense $ 9,953 Other revenue: Additional stability studies $ 11,024 Six Months Ended June 30, 2018 Diagnostics Royalty revenue: Europe $ 7,460 License revenue: NAV4694 sublicense $ 257,709 Other revenue: Additional stability studies $ 15,037 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m not may NAV4694 not Through June 30, 2019, not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets, during the three six June 30, 2019 2018. Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Total deferred revenue, beginning of period $ 700,000 $ 711,024 $ 711,024 $ 26,061 Impact of adoption of ASU 2014-09 and related standards — — — 700,000 Revenue deferred related to sublicense 495,000 10,000 495,000 10,000 Revenue recognized from satisfaction of performance obligations — — (11,024 ) (15,037 ) Total deferred revenue, end of period $ 1,195,000 $ 721,024 $ 1,195,000 $ 721,024 The Company had trade receivables of approximately $0 $12,000 June 30, 2019 December 31, 2018. In addition to revenue from contracts from customers, we also generate revenue from NIH grants to support various product development initiatives. The revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea does not not

Note 4 - Fair Value

Note 4 - Fair Value	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4 . Fair Value The Company’s available-for-sale securities consist of certificates of deposit which are measured using Level 2 MT issued warrants to purchase MT Common Stock with certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value on the consolidated balance sheets. The estimated fair value of the MT warrants is $63,000 June 30, 2019 December 31, 2018, The following tables set forth, by level, financial assets and liabilities measured at fair value on a recurring basis. Assets and Liabilities Measured at Fair Value on a Recurring Basis as of June 30 , 2019 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 200,188 $ — $ 200,188 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 Assets and Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2018 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 799,270 $ — $ 799,270 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 a. Valuation Processes-Level 3 third b. Sensitivity Analysis-Level 3 may may not There were no 1 2 six June 30, 2019 2018. no 1 2 six June 30, 2019 2018. 3 no 3 six June 30, 2019 2018.

Note 5 - Stock-based Compensati

Note 5 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	5 . Stock-Based Compensation For the three June 30, 2019 2018, $66,000 $79,000, six June 30, 2019 2018, $128,000 $217,000, not three six June 30, 2019 2018. A summary of the status of our stock options as of June 30, 2019, six Six Months Ended June 30 , 201 9 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of period 157,915 $ 24.82 Granted 95,250 5.89 Exercised — — Canceled and Forfeited (5,304 ) 8.94 Expired (9,041 ) 31.21 Outstanding at end of period 238,820 $ 17.38 7.7 $ — Exercisable at end of period 78,074 $ 33.81 5.1 $ — A summary of the status of our unvested restricted stock as of June 30, 2019, six Six Months Ended June 30 , 201 9 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 5,000 $ 7.42 Granted 15,000 2.75 Vested (5,000 ) 7.42 Forfeited — — Unvested at end of period 15,000 $ 2.75 As of June 30, 2019, $116,000 1.0

Note 6 - Loss Per Share

Note 6 - Loss Per Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	6 . Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the six June 30, 2019 2018 1,495,948 948,959 The Company’s unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 15,000 7,500 six June 30, 2019 2018,

Note 7 - Investment in Macropha

Note 7 - Investment in Macrophage Therapeutics, Inc.	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	7 . Investment in Macrophage Therapeutics, Inc. In August 2018, 5% one 10 not On February 11, 2019, February 19, 2019, March 1, 2019 February 20, 2019, may On February 20, 2019, April 26, 2019, June 13, 2019, third July 5, 2019, not Also on February 20, 2019, June 12, 2019, not May 23, 2019 On July 26, 2019, 11.

Note 8 - Accounts Payable, Accr

Note 8 - Accounts Payable, Accrued Liabilities and Other	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	8. Accounts Payable , Accrued Liabilities and Other Accrued liabilities and other at June 30, 2019 December 31, 2018 $309,000 $1.6

Note 9 - Notes Payable

Note 9 - Notes Payable	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	9 . Notes Payable Platinum-Montaur Life Sciences LLC In July 2012, $50 March 2017, $7.7 November 2018, 925,000 817,857 $3.2 $2.2 $1.0 11. During the six June 30, 2018, $85,000 IPFS Corporation In November 2017, $396,000 4.0%. ten $40,000, August 2018. November 2018, $393,000 5.1%. ten $40,000, August 2019. Interest expense related to the IPFS notes payable totaled $6,000 $4,000 six June 30, 2019 2018, $80,000 $316,000 June 30, 2019 December 31, 2018, Summary During the three June 30, 2019 2018, $2,000 $45,000, $0 $43,000 three June 30, 2019 2018, six June 30, 2019 2018, $6,000 $89,000, $0 $85,000 six June 30, 2019 2018,

Note 10 - Leases

Note 10 - Leases	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Leases We currently lease approximately 5,000 4995 June 2020 $3,000. 2,000 560 $3,000. March 31, 2019 not In addition, we currently lease approximately 25,000 5600 October 2022, $26,000 2019. June 2017, $39,000 October 2022. We also currently lease a vehicle. The lease term expires in September 2021, $300. We adopted ASU 2016 02, Leases (Topic 842 January 1, 2019. 2016 02 Operating Lease Right- of-Use Assets Operating Lease Liabilities Terminated Lease Liability Deferred Rent Pre-adoption balance $ — $ — $ 589,173 $ 2,587 Change 406,842 998,602 (589,173 ) (2,587 ) Post-adoption balance $ 406,842 $ 998,602 $ — $ — All of our leases are operating leases and are included in right-of-use lease assets, current lease liabilities and noncurrent lease liabilities on our consolidated balance sheets. These assets and liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term operating leases which have an initial term of 12 not Lease expense for operating leases is recognized on a straight-line basis over the lease term. Lease expense is included in selling, general and administrative expenses on our consolidated statements of operations. Total operating lease expense was $55,000 $121,000 three six June 30, 2019, $94,000 $189,000 three six June 30, 2019, The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of June 30, 2019. Maturity of Lease Liabilities Operating Lease Payments 2019 (remaining) $ 153,858 2020 319,034 2021 306,781 2022 253,339 Total undiscounted operating lease payments 1,033,012 Less imputed interest 168,313 Present value of operating lease liabilities $ 864,699 Balance Sheet Classification Current lease liabilities $ 250,946 Noncurrent lease liabilities 613,753 Total operating lease liabilities $ 864,699 Other Information Weighted-average remaining lease term for operating leases (in years) 3.2 Weighted-average discount rate for operating leases 12.3 % An initial right-of-use lease asset of $407,000 2016 02. $185,000 six June 30, 2019

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 1 . Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. CRG Litigation As disclosed in the Company’s Annual Report on Form 10 December 2017, $66.0 $66.0 $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 $4.1 $7.0 On April 9, 2018, $7.1 414, 414” $4.1 $59.0 The Company has also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio (the “Ohio Court”) related to Navidea’s claims that the Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the Lenders in connection with the Global Settlement Agreement reached in 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 7, 2019, June 28, 2019. CRG filed another lawsuit in the Texas Court in April 2018. not $7.1 414 2. Platinum Li tigation In November 2017, $1.9 March 3, 2017, October 31, 2018, no On November 30, 2018, January 22, 2019, February 26, 2019, September 5, 2019 9. Goldberg Agreement and Litigation In August 2018, one 1,175,000 1,175,000 18 5% November 2018, 925,000 250,000 10 not On February 11, 2019, February 19, 2019, March 1, 2019 February 20, 2019, may On February 20, 2019, April 26, 2019, June 13, 2019, third July 5, 2019, not Also on February 20, 2019, June 12, 2019, not May 23, 2019 On July 26, 2019, 7. NYSE American Continued Listing Standards On August 14, 2018, not not 1003 $4.0 three four $2.1 June 30, 2018, four five December 31, 2017. In addition, the Deficiency Letter stated that the Staff determined that the Company’s securities have been selling for a low price per share for a substantial period of time and, pursuant to Section 1003 $0.001 Navidea was required to submit a plan to the NYSE American by September 14, 2018 February 14, 2020. On October 25, 2018, not 1003 $6.0 five $2.1 June 30, 2018, five December 31, 2017. The Company is required to provide quarterly updates to the NYSE American staff (the “Staff”) concurrent with its interim/annual SEC filings. If Navidea fails to regain compliance with the stockholders’ equity standards by February 14, 2020, On April 2, 2019, not 1003 $2.0 two three 10 $1.7 December 31, 2018, five December 31, 2018. The NYSE Letter also required the Company to regain compliance with the price standard in order to be considered for continued trading through its equity plan period end date of February 14, 2020, one twenty April 26, 2019. On April 30, 2019, 1003 1003 1003 1003 February 14, 2020, In accordance with ASC Topic 450, Contingencies not

Note 12 - Equity

Note 12 - Equity	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 2 . Equity On March 22, 2019, $3.0 March 22, 2019 ( $50,000 $2.80, not June 15, 2019. No June 15, 2019 On June 18, 2019, 8,000,000 $0.75 8,000,000 4,000,000 $0.75 4,000,000 $0.69375 30 1,200,000 $0.69375. not The Company paid the Underwriter (a) a management fee equal to 1.0% $50,000 $100,000 $10,000 $5,555,000. 2b 3 Tc99m During the six June 30, 2018, 55,938 $317,000 2017 During the six June 30, 2019 2018, 8,128 4,734 401 $20,000 $36,000,

Note 13 - Stock Warrants

Note 13 - Stock Warrants	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	1 3 . Stock Warrants Pursuant to the Underwriting Agreement related to the June 18, 2019 600,000 7.5% five $0.9375 125% $261,000 88.6%, 1.8% $0. At June 30, 2019, 1.4 $0.20 $50.00 $13.65 two 16.2 In addition, at June 30, 2019, 300 $2,000

Note 14 - Income Taxes

Note 14 - Income Taxes	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 4 . Income Taxes Income taxes are accounted for under the asset and liability method in accordance with Accounting Standards Codification 740, Income Taxes Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not June 30, 2019 December 31, 2018, In assessing the realizability of DTAs, management considers whether it is more likely than not not not not June 30, 2019 The Tax Cuts and Jobs Act was signed into law on December 22, 2017. 35% 21%, January 1, 2018. 2018, 2019 2020. may 2018 2020, 50% 2018, 2019 2020 2021. 50% $1.2 June 30, 2019 December 31, 2018. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no June 30, 2019 December 31, 2018 not twelve June 30, 2019, 2015 2018 As of June 30, 2019, $130.9 $20.3 $8.7

Note 15 - Segments

Note 15 - Segments	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 5 . Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no two 99m NAV4694 April 2018), The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended June 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 5,940 $ — $ — $ 5,940 License revenue 9,953 — — 9,953 Grant and other revenue 196,630 47,569 — 244,199 Total revenue 212,523 47,569 — 260,092 Cost of revenue 238 — — 238 Research and development expenses 775,462 295,180 — 1,070,642 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,062 1,821,812 1,824,874 Depreciation and amortization (2) — — 36,726 36,726 Loss from operations (3) (563,177 ) (250,673 ) (1,858,538 ) (2,672,388 ) Other expense (4) — — (1,590 ) (1,590 ) Income tax benefit 35 16 117 168 Net loss from continuing operations (563,142 ) (250,657 ) (1,860,011 ) (2,673,810 ) Income from discontinued operations, net of tax 632 — — 632 Net loss (562,510 ) (250,657 ) (1,860,011 ) (2,673,178 ) Total assets, net of depreciation and amortization: United States $ 220,334 $ 11,235 $ 7,892,312 $ 8,123,881 International 6,514 — — 6,514 Capital expenditures — — — — Three Months Ended June 30, 201 8 Diagnostics Therapeutics Corporate Total Royalty revenue $ 6,665 $ — $ — $ 6,665 License revenue 257,709 — — 257,709 Grant and other revenue 156,889 120,864 — 277,753 Total revenue 421,263 120,864 — 542,127 Cost of revenue 35,392 — — 35,392 Research and development expenses 913,158 229,560 — 1,142,718 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 16,630 1,735,258 1,751,888 Depreciation and amortization (2) — — 37,511 37,511 Loss from operations (3) (527,287 ) (125,326 ) (1,772,769 ) (2,425,382 ) Other expense (4) — — (20,719 ) (20,719 ) Income tax benefit 2,356 560 8,013 10,929 Net loss from continuing operations (524,931 ) (124,766 ) (1,785,475 ) (2,435,172 ) Loss from discontinued operations, net of tax (1,938 ) — — (1,938 ) Gain on sale of discontinued operations, net of tax 43,053 — — 43,053 Net loss (483,816 ) (124,766 ) (1,785,475 ) (2,394,057 ) Total assets, net of depreciation and amortization: United States $ 409,769 $ 87,751 $ 8,139,434 $ 8,636,954 International 22,147 — 1,391 23,538 Capital expenditures — — 3,165 3,165 Six Months Ended June 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,090 $ — $ — $ 9,090 License revenue 9,953 — — 9,953 Grant and other revenue 232,621 50,052 — 282,673 Total revenue 251,664 50,052 — 301,716 Cost of revenue 6,364 — — 6,364 Research and development expenses 1,516,045 295,180 — 1,811,225 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 14,776 3,501,835 3,516,611 Depreciation and amortization (2) — — 73,505 73,505 Loss from operations (3) (1,270,745 ) (259,904 ) (3,575,340 ) (5,105,989 ) Other income (4) — — 7,122 7,122 Provision for income tax (177 ) (36 ) (495 ) (708 ) Net loss from continuing operations (1,270,922 ) (259,940 ) (3,568,713 ) (5,099,575 ) Loss from discontinued operations, net of tax (2,665 ) — — (2,665 ) Net loss (1,273,587 ) (259,940 ) (3,568,713 ) (5,102,240 ) Total assets, net of depreciation and amortization: United States $ 220,334 $ 11,235 $ 7,892,312 $ 8,123,881 International 6,514 — — 6,514 Capital expenditures — — — — Six Months Ended June 30, 201 8 Diagnostics Therapeutics Corporate Total Royalty revenue $ 7,460 $ — $ — $ 7,460 License revenue 257,709 — — 257,709 Grant and other revenue 389,325 164,078 — 553,403 Total revenue 654,494 164,078 — 818,572 Cost of revenue 35,710 — — 35,710 Research and development expenses 1,698,169 443,505 — 2,141,674 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 25,237 3,465,036 3,490,273 Depreciation and amortization (2) — — 75,498 75,498 Loss from operations (3) (1,079,385 ) (304,664 ) (3,540,534 ) (4,924,583 ) Other expense (4) — — (4,259,480 ) (4,259,480 ) Income tax benefit 1,284 363 9,282 10,929 Net loss from continuing operations (1,078,101 ) (304,301 ) (7,790,732 ) (9,173,134 ) Loss from discontinued operations, net of tax (1,938 ) — — (1,938 ) Gain on sale of discontinued operations, net of tax 43,053 — — 43,053 Net loss (1,036,986 ) (304,301 ) (7,790,732 ) (9,132,019 ) Total assets, net of depreciation and amortization: United States $ 409,769 $ 87,751 $ 8,139,434 $ 8,636,954 International 22,147 — 1,391 23,538 Capital expenditures — — 3,165 3,165 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 ) Depreciation and amortization is reflected in selling, general and administrative expenses ( $36,726 $37,511 three June 30, 2019 2018, $73,505 $75,498 six June 30, 2019 2018, ( 3 ) Loss from operations does not ( 4 ) Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not

Note 16 - Supplemental Disclosu

Note 16 - Supplemental Disclosure for Statements of Cash Flows	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	1 6 . Supplemental Disclosure for Statements of Cash Flows During the six June 30, 2019 2018, $6,000 $4,000, six June 30, 2019 2018, 8,128 4,734 401 $20,000 $36,000,

Note 17 - Subsequent Events

Note 17 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	1 7 . Subsequent Events The Company has evaluated events and transactions subsequent to June 30, 2019 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: June 30, 2019 three six June 30, 2019 2018 June 30, 2019 not December 31, 2018, 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiary, Navidea Biopharmaceuticals Limited, and our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. On April 26, 2019, one twenty twenty one 201.0 10.1 not 300.0 $0.001 January 1, 2018. not
Fair Value of Financial Instruments, Policy [Policy Text Block]	b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents , available-for-sale securities, accounts and other receivables, and accounts payable: ( 2 Notes payable: June 30, 2019 December 31, 2018 June 30, 2019, $80,000, $80,000. December 31, 2018, $316,000, $316,000. 9. ( 3 Derivative liabilities: $63,000 June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018 4.
Revenue [Policy Text Block]	c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3.
New Accounting Pronouncements, Policy [Policy Text Block]	d. Recent ly Adopted Accounting Standards : February 2016, No. 2016 02, Leases (Topic 842 2016 02 842 In July 2018, No. 2018 10, Codification Improvements to Topic 842, No. 2018 11, Targeted Improvements to Topic 842, 2018 10 842 2016 02, Leases (Topic 842 2018 11 840, Leases 840 840. 2018 10 2018 11 2016 02 December 15, 2018. The Company adopted ASU 2016 02, 2018 10 2018 11 January 1, 2019 not 12 The adoption of ASU 2016 02 $407,000 January 1, 2019 2016 02 not 10. In June 2018, No. 2018 07, Compensation—Stock Compensation (Topic 718 2018 07 718 718 2018 07 718 718 not 1 2 606, Revenue from Contracts with Customers 2018 07 December 15, 2018, 2018 07 not In July 2018, No. 2018 09, Codification Improvements 2018 09 2018 09 December 15, 2018 2018 09 not

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	T hree Months Ended June 30 , 2019 Diagnostics Royalty revenue: Europe $ 5,940 License revenue: NAV4694 sublicense $ 9,953 T hree Months Ended June 30 , 2018 Diagnostics Royalty revenue: Europe $ 6,665 License revenue: NAV4694 sublicense $ 257,709 Six Months Ended June 30, 2019 Diagnostics Royalty revenue: Europe $ 9,090 License revenue: NAV4694 sublicense $ 9,953 Other revenue: Additional stability studies $ 11,024 Six Months Ended June 30, 2018 Diagnostics Royalty revenue: Europe $ 7,460 License revenue: NAV4694 sublicense $ 257,709 Other revenue: Additional stability studies $ 15,037
Contract with Customer, Asset and Liability [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Total deferred revenue, beginning of period $ 700,000 $ 711,024 $ 711,024 $ 26,061 Impact of adoption of ASU 2014-09 and related standards — — — 700,000 Revenue deferred related to sublicense 495,000 10,000 495,000 10,000 Revenue recognized from satisfaction of performance obligations — — (11,024 ) (15,037 ) Total deferred revenue, end of period $ 1,195,000 $ 721,024 $ 1,195,000 $ 721,024

Note 4 - Fair Value (Tables)

Note 4 - Fair Value (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured at Fair Value on a Recurring Basis as of June 30 , 2019 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 200,188 $ — $ 200,188 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 Assets and Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2018 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 799,270 $ — $ 799,270 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000

Note 5 - Stock-based Compensa_2

Note 5 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Six Months Ended June 30 , 201 9 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of period 157,915 $ 24.82 Granted 95,250 5.89 Exercised — — Canceled and Forfeited (5,304 ) 8.94 Expired (9,041 ) 31.21 Outstanding at end of period 238,820 $ 17.38 7.7 $ — Exercisable at end of period 78,074 $ 33.81 5.1 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Six Months Ended June 30 , 201 9 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 5,000 $ 7.42 Granted 15,000 2.75 Vested (5,000 ) 7.42 Forfeited — — Unvested at end of period 15,000 $ 2.75

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Operating Lease Right- of-Use Assets Operating Lease Liabilities Terminated Lease Liability Deferred Rent Pre-adoption balance $ — $ — $ 589,173 $ 2,587 Change 406,842 998,602 (589,173 ) (2,587 ) Post-adoption balance $ 406,842 $ 998,602 $ — $ —
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease Payments 2019 (remaining) $ 153,858 2020 319,034 2021 306,781 2022 253,339 Total undiscounted operating lease payments 1,033,012 Less imputed interest 168,313 Present value of operating lease liabilities $ 864,699 Balance Sheet Classification Current lease liabilities $ 250,946 Noncurrent lease liabilities 613,753 Total operating lease liabilities $ 864,699 Other Information Weighted-average remaining lease term for operating leases (in years) 3.2 Weighted-average discount rate for operating leases 12.3 %

Note 15 - Segments (Tables)

Note 15 - Segments (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended June 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 5,940 $ — $ — $ 5,940 License revenue 9,953 — — 9,953 Grant and other revenue 196,630 47,569 — 244,199 Total revenue 212,523 47,569 — 260,092 Cost of revenue 238 — — 238 Research and development expenses 775,462 295,180 — 1,070,642 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,062 1,821,812 1,824,874 Depreciation and amortization (2) — — 36,726 36,726 Loss from operations (3) (563,177 ) (250,673 ) (1,858,538 ) (2,672,388 ) Other expense (4) — — (1,590 ) (1,590 ) Income tax benefit 35 16 117 168 Net loss from continuing operations (563,142 ) (250,657 ) (1,860,011 ) (2,673,810 ) Income from discontinued operations, net of tax 632 — — 632 Net loss (562,510 ) (250,657 ) (1,860,011 ) (2,673,178 ) Total assets, net of depreciation and amortization: United States $ 220,334 $ 11,235 $ 7,892,312 $ 8,123,881 International 6,514 — — 6,514 Capital expenditures — — — — Three Months Ended June 30, 201 8 Diagnostics Therapeutics Corporate Total Royalty revenue $ 6,665 $ — $ — $ 6,665 License revenue 257,709 — — 257,709 Grant and other revenue 156,889 120,864 — 277,753 Total revenue 421,263 120,864 — 542,127 Cost of revenue 35,392 — — 35,392 Research and development expenses 913,158 229,560 — 1,142,718 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 16,630 1,735,258 1,751,888 Depreciation and amortization (2) — — 37,511 37,511 Loss from operations (3) (527,287 ) (125,326 ) (1,772,769 ) (2,425,382 ) Other expense (4) — — (20,719 ) (20,719 ) Income tax benefit 2,356 560 8,013 10,929 Net loss from continuing operations (524,931 ) (124,766 ) (1,785,475 ) (2,435,172 ) Loss from discontinued operations, net of tax (1,938 ) — — (1,938 ) Gain on sale of discontinued operations, net of tax 43,053 — — 43,053 Net loss (483,816 ) (124,766 ) (1,785,475 ) (2,394,057 ) Total assets, net of depreciation and amortization: United States $ 409,769 $ 87,751 $ 8,139,434 $ 8,636,954 International 22,147 — 1,391 23,538 Capital expenditures — — 3,165 3,165 Six Months Ended June 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,090 $ — $ — $ 9,090 License revenue 9,953 — — 9,953 Grant and other revenue 232,621 50,052 — 282,673 Total revenue 251,664 50,052 — 301,716 Cost of revenue 6,364 — — 6,364 Research and development expenses 1,516,045 295,180 — 1,811,225 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 14,776 3,501,835 3,516,611 Depreciation and amortization (2) — — 73,505 73,505 Loss from operations (3) (1,270,745 ) (259,904 ) (3,575,340 ) (5,105,989 ) Other income (4) — — 7,122 7,122 Provision for income tax (177 ) (36 ) (495 ) (708 ) Net loss from continuing operations (1,270,922 ) (259,940 ) (3,568,713 ) (5,099,575 ) Loss from discontinued operations, net of tax (2,665 ) — — (2,665 ) Net loss (1,273,587 ) (259,940 ) (3,568,713 ) (5,102,240 ) Total assets, net of depreciation and amortization: United States $ 220,334 $ 11,235 $ 7,892,312 $ 8,123,881 International 6,514 — — 6,514 Capital expenditures — — — — Six Months Ended June 30, 201 8 Diagnostics Therapeutics Corporate Total Royalty revenue $ 7,460 $ — $ — $ 7,460 License revenue 257,709 — — 257,709 Grant and other revenue 389,325 164,078 — 553,403 Total revenue 654,494 164,078 — 818,572 Cost of revenue 35,710 — — 35,710 Research and development expenses 1,698,169 443,505 — 2,141,674 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 25,237 3,465,036 3,490,273 Depreciation and amortization (2) — — 75,498 75,498 Loss from operations (3) (1,079,385 ) (304,664 ) (3,540,534 ) (4,924,583 ) Other expense (4) — — (4,259,480 ) (4,259,480 ) Income tax benefit 1,284 363 9,282 10,929 Net loss from continuing operations (1,078,101 ) (304,301 ) (7,790,732 ) (9,173,134 ) Loss from discontinued operations, net of tax (1,938 ) — — (1,938 ) Gain on sale of discontinued operations, net of tax 43,053 — — 43,053 Net loss (1,036,986 ) (304,301 ) (7,790,732 ) (9,132,019 ) Total assets, net of depreciation and amortization: United States $ 409,769 $ 87,751 $ 8,139,434 $ 8,636,954 International 22,147 — 1,391 23,538 Capital expenditures — — 3,165 3,165

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Apr. 18, 2019	Jun. 30, 2019USD ($)$ / sharesshares	Apr. 26, 2019$ / sharesshares	Apr. 25, 2019shares	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Jun. 30, 2018$ / shares
Common Stock, Shares, Outstanding, Ending Balance | shares		18,059,406	10,100,000			10,019,535
Common Stock, Shares Authorized | shares		300,000,000	300,000,000			300,000,000
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.001	$ 0.001			$ 0.001	$ 0.001
Notes Payable, Fair Value Disclosure		$ 80,000				$ 316,000
Notes Payable, Current, Total		80,024				316,074
Derivative Liability, Total		63,000				63,000
Operating Lease, Right-of-Use Asset		336,882			$ 406,842
Operating Lease, Liability, Total		$ 864,699			998,602
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset					407,000
Operating Lease, Liability, Total					$ 407,000
Before Reverse Stock Split [Member]
Common Stock, Shares, Outstanding, Ending Balance | shares				201,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Jun. 18, 2019	Dec. 31, 2017	Nov. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Apr. 26, 2019	Dec. 31, 2018
Common Stock, Par or Stated Value Per Share				$ 0.001	$ 0.001	$ 0.001	$ 0.001
Proceeds from Issuance of Common Stock				$ 6,046,915	$ 200
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues	8,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Shares Issued, Price Per Share	$ 0.75
Proceeds from Issuance of Common Stock	$ 5,555,000
Underwritten Public Offering [Member] | John K. Scott, Jr. [Member]
Stock Issued During Period, Shares, New Issues	4,000,000
Shares Issued, Price Per Share	$ 0.75
Underwritten Public Offering [Member] | Underwriter [Member]
Stock Issued During Period, Shares, New Issues	4,000,000
Shares Issued, Price Per Share	$ 0.69375
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration		$ 4,100,000		$ 4,100,000
Platinum-Montaur Life Sciences LLC Litigation [Member]
Loss Contingency, Damages Sought, Value			$ 1,900,000

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Contract with Customer, Payment Term, Minimum			15 days
Contract with Customer, Payment Term, Maximum			90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	$ 0		$ 0
Revenue from Contract with Customer, Including Assessed Tax	16,000	$ 264,000	30,000	$ 265,000
Contract with Customer, Asset, Impairment Loss	0	0	0	0
Contract with Customer, Performance Obligation Satisfied in Previous Period	0	$ 0	0	$ 0
Capitalized Contract Cost, Net, Total	0		0
Contract with Customer, Asset, after Allowance for Credit Loss, Total	$ 0		$ 0		$ 12,000
INDIA
Contract with Customer, Term of Contract			8 years
CHINA
Contract with Customer, Term of Contract			10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue from contract with customer	$ 16,000	$ 264,000	$ 30,000	$ 265,000
Royalty [Member]
Revenue from contract with customer	5,940	6,665	9,090	7,460
Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	5,940	6,665	9,090	7,460
License [Member]
Revenue from contract with customer	9,953	257,709	9,953	257,709
License [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	9,953	257,709	9,953	257,709
Product and Service, Other [Member] | Diagnostics Segment [Member]
Revenue from contract with customer			11,024	15,037
Europe [Member] | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	$ 5,940	$ 6,665	$ 9,090	$ 7,460

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total deferred revenue, beginning of period	$ 700,000	$ 711,024	$ 711,024	$ 26,061
Impact of adoption of ASU 2014-09 and related standards				700,000
Revenue deferred related to sublicense	495,000	10,000	495,000	10,000
Revenue recognized from satisfaction of performance obligations			(11,024)	(15,037)
Total deferred revenue, end of period	$ 1,195,000	$ 721,024	$ 1,195,000	$ 721,024

Note 4 - Fair Value (Details Te

Note 4 - Fair Value (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Derivative Liability, Total	$ 63,000		$ 63,000
Fair Value, Inputs, Level 1 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	$ 0
Fair Value, Inputs, Level 2 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total	0	$ 0
Other Liabilities [Member]
Derivative Liability, Total	$ 63,000		$ 63,000

Note 4 - Fair Value - Financial

Note 4 - Fair Value - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)		Jun. 30, 2019	Dec. 31, 2018
Derivative Liability, Total		$ 63,000	$ 63,000
Fair Value, Recurring [Member]
Certificates of deposit		200,188	799,270
Derivative Liability, Total	[1],[2]	63,000	63,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Certificates of deposit
Derivative Liability, Total	[1],[2]
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Certificates of deposit		200,188	799,270
Derivative Liability, Total	[1],[2]
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Certificates of deposit
Derivative Liability, Total	[1],[2]	$ 63,000	$ 63,000
[1]	a. Valuation Processes-Level 3 Measurements: The Company utilizes third-party valuation services that use complex models such as Monte Carlo simulation to estimate the value of our financial liabilities.
[2]	b. Sensitivity Analysis-Level 3 Measurements: Changes in the valuation of MT as a whole may cause material changes in the fair value of the MT warrants. Significant increases (decreases) in the valuation of MT, such as may be the result of additional financing, could result in a higher (lower) fair value measurement. A change in the valuation of MT would not necessarily result in a directionally similar change in the value of the MT warrants.

Note 5 - Stock-based Compensa_3

Note 5 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Expense	$ 66,000	$ 79,000	$ 128,000	$ 217,000
Share-based Payment Arrangement, Expense, Tax Benefit	0	$ 0	0	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 116,000		$ 116,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			1 year

Note 5 - Stock-based Compensa_4

Note 5 - Stock-based Compensation - Summary of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Outstanding at beginning of period (in shares) | shares	157,915
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 24.82
Granted (in shares) | shares	95,250
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 5.89
Exercised (in shares) | shares
Exercised, weighted average exercise price (in dollars per share) | $ / shares
Canceled and Forfeited (in shares) | shares	(5,304)
Canceled and Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 8.94
Expired (in shares) | shares	(9,041)
Expired (in dollars per share) | $ / shares	$ 31.21
Outstanding at end of period (in shares) | shares	238,820
Outstanding at end of period (in dollars per share) | $ / shares	$ 17.38
Outstanding at end of period (Year)	7 years 255 days
Outstanding at end of period | $
Exercisable at end of period (in shares) | shares	78,074
Exercisable at end of period (in dollars per share) | $ / shares	$ 33.81
Exercisable at end of period (Year)	5 years 36 days
Exercisable at end of period | $

Note 5 - Stock-based Compensa_5

Note 5 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Unvested at beginning of period (in shares) | shares	5,000
Unvested at beginning of period (in dollars per share) | $ / shares	$ 7.42
Granted (in shares) | shares	15,000
Granted, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.75
Vested (in shares) | shares	(5,000)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 7.42
Forfeited (in shares) | shares
Forfeited, weighted average grant-date fair value (in dollars per share) | $ / shares
Unvested at end of period (in shares) | shares	15,000
Unvested at end of period (in dollars per share) | $ / shares	$ 2.75

Note 6 - Loss Per Share (Detail

Note 6 - Loss Per Share (Details Textual) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,495,948	948,959
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,000	7,500

Note 7 - Investment in Macrop_2

Note 7 - Investment in Macrophage Therapeutics, Inc. (Details Textual)	Aug. 31, 2018
MT [Member] | Dr. Michael Goldberg [Member]
Resignation Agreement, Subidiary Percentage Ownership After Signing	5.00%

Note 8 - Accounts Payable, Ac_2

Note 8 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Termination Costs, Bonuses and Director Fees [Member] | Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 309,000	$ 1,600,000

Note 9 - Notes Payable (Details

Note 9 - Notes Payable (Details Textual) - USD ($)	1 Months Ended			3 Months Ended			6 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Mar. 31, 2017	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Jul. 31, 2012
Gain (Loss) on Extinguishment of Debt, Total								$ (4,265,434)
Interest Expense, Debt, Total				2,000		45,000	6,000	89,000
Notes Payable, Current, Total				80,024			80,024		$ 316,074
Interest Expense Compounded				$ 0		$ 43,000	0	85,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues				8,000,000	17,857
Former Chief Executive Officer and President [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues	925,000
Platinum Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity										$ 50,000,000
Interest Expense, Debt, Excluding Amortization								85,000
Platinum Loan Agreement [Member] | Former Chief Executive Officer and President [Member]
Debt Conversion, Original Debt, Amount	$ 2,200,000
Gain (Loss) on Extinguishment of Debt, Total	$ (1,000,000)
Platinum Loan Agreement [Member] | Former Chief Executive Officer and President [Member] | Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued	817,857
Debt Conversion, Converted Instrument, Amount	$ 3,200,000
Platinum Loan Agreement [Member] | PPCO [Member]
Repayments of Debt			$ 7,700,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member]
Notes Payable, Current, Total				$ 80,000			80,000		$ 316,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount	$ 393,000	$ 396,000
Debt Instrument, Interest Rate, Stated Percentage	5.10%	4.00%
Debt Instrument, Term	300 days	300 days
Debt Instrument, Periodic Payment, Total	$ 40,000	$ 40,000
Interest Expense, Debt, Total							$ 6,000	$ 4,000

Note 10 - Leases (Details Textu

Note 10 - Leases (Details Textual)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2019USD ($)ft²	Mar. 31, 2019USD ($)ft²	Jun. 30, 2019USD ($)ft²	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Operating Lease, Expense		$ 55,000		$ 121,000
Sublease Income		94,000		189,000
Operating Lease, Right-of-Use Asset		$ 336,882		336,882	$ 406,842
Operating Lease, Payments				$ 185,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset					$ 407,000
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property | ft²		5,000		5,000
Operating Lease, Monthly Base Rent				$ 3,000
Office Space at 560 Sylvan Avenue, Englewood Cliffs, New Jersey [Member]
Area of Real Estate Property | ft²			2,000
Operating Lease, Monthly Base Rent			$ 3,000
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property | ft²		25,000		25,000
Operating Lease, Monthly Base Rent				$ 26,000
Operating Lease, Sublease, Monthly Rent Revenue	$ 39,000
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent				$ 300

Note 10 - Leases - Impact of th

Note 10 - Leases - Impact of the Adoption of ASU 2016-02 on Our Balance Sheet (Details) - USD ($)	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease Right-of-use Assets, Pre-adoption balance	$ 336,882	$ 406,842
Operating Lease Liabilities, Pre-adoption balance	$ 864,699	998,602
Terminated Lease Liability, Pre-adoption balance
Deferred Rent, Pre-adoption balance
Previous Accounting Guidance [Member]
Operating Lease Right-of-use Assets, Pre-adoption balance
Operating Lease Liabilities, Pre-adoption balance
Terminated Lease Liability, Pre-adoption balance		589,173
Deferred Rent, Pre-adoption balance		2,587
Adjustments for New Accounting Pronouncement [Member]
Operating Lease Right-of-use Assets, Pre-adoption balance		406,842
Operating Lease Liabilities, Pre-adoption balance		998,602
Terminated Lease Liability, Pre-adoption balance		(589,173)
Deferred Rent, Pre-adoption balance		$ (2,587)

Note 10 - Leases - Amount, Timi

Note 10 - Leases - Amount, Timing and Uncertainty of Cash Flows Arising From Operating Leases (Details) - USD ($)	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
2019 (remaining)	$ 153,858
2020	319,034
2021	306,781
2022	253,339
Total undiscounted operating lease payments	1,033,012
Less imputed interest	168,313
Present value of operating lease liabilities	864,699	$ 998,602
Current lease liabilities	250,946
Noncurrent lease liabilities	$ 613,753
Weighted-average remaining lease term for operating leases (in years) (Year)	3 years 73 days
Weighted-average discount rate for operating leases	12.30%

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual)

Apr. 18, 2019

Aug. 14, 2018

Apr. 09, 2018USD ($)

Jan. 16, 2018USD ($)

Mar. 03, 2017USD ($)

Nov. 30, 2018shares

Dec. 31, 2017USD ($)

Nov. 30, 2017USD ($)

Jun. 30, 2019USD ($)$ / sharesshares

Mar. 31, 2019shares

Jun. 30, 2019USD ($)$ / shares

Apr. 26, 2019$ / shares

Dec. 31, 2018USD ($)$ / shares

Aug. 31, 2018shares

Jun. 30, 2018USD ($)$ / shares

Stockholders' Equity Attributable to Parent, Ending Balance

$ 2,263,201

$ 2,263,201

$ 1,742,139

$ 2,100,000

Common Stock, Par or Stated Value Per Share | $ / shares

$ 0.001

$ 0.001

$ 0.001

$ 0.001

$ 0.001

Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

20

Common Stock [Member]

Stock Issued During Period, Shares, New Issues | shares

8,000,000

17,857

Former Chief Executive Officer and President [Member]

Common Stock Shares Provided by Agreement | shares

1,175,000

Common Stock Shares Provided by Agreement, Escrow Period

1 year 180 days

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues | shares

925,000

Stock Issued During Period, Shares, New Issues Placed in Escrow | shares

250,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]

Ownership Percentage

5.00%

5.00%

Maximum [Member] | Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

20

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Additional Amount

$ 7,000,000

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

4,100,000

$ 4,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Term Loan Agreement [Member]

Repayments of Debt

$ 7,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | CRG [Member] | Term Loan Agreement [Member]

Repayments of Debt

59,000,000

Platinum-Montaur Life Sciences LLC Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Texas Court Judgement Appeal [Member]

Loss Contingency, Damages Sought, Value

$ 4,100,000

CRG [Member] | CRG Loan Agreement, Texas Case [Member] | Minimum [Member]

Litigation Settlement, Amount Awarded to Other Party

$ 66,000,000

CRG [Member] | Global Settlement Agreement [Member] | Maximum [Member]

Litigation Settlement, Amount Awarded to Other Party

$ 66,000,000

Note 12 - Equity (Details Textu

Note 12 - Equity (Details Textual) - USD ($)	Jun. 18, 2019	Mar. 22, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 15, 2019
Stock Issued During Period, Value, New Issues			$ 5,166,441	$ 50,000
Payments of Stock Issuance Costs							$ 572,271
Proceeds from Issuance of Common Stock							$ 6,046,915	$ 200
Stock Issued During Period, Shares, Issued for Employee Bonuses								55,938
Stock Issued During Period, Value, Issued for Employee Bonuses					$ 151,881	$ 165,021		$ 317,000
Stock Issued During Period, Shares, Employee Benefit Plan							8,128	4,734
Stock Issued During Period, Value, Employee Benefit Plan			$ 19,588			$ 35,980	$ 20,000	$ 36,000
Private Placement [Member] | Investor [Member]
Stock Issued During Period, Value, New Issues		$ 50,000
Shares Issued, Price Per Share		$ 2.80
Private Placement [Member] | Maximum [Member]
Stock Purchase Agreement, Maximum Value									$ 3,000,000
Underwritten Public Offering [Member]
Shares Issued, Price Per Share	$ 0.75
Stock Issued During Period, Shares, New Issues	8,000,000
Stock Issued, Management Fee, Percentage	1.00%
Proceeds from Issuance of Common Stock	$ 5,555,000
Underwritten Public Offering [Member] | Non-accountable Expenses [Member]
Payments of Stock Issuance Costs	50,000
Underwritten Public Offering [Member] | Fees and Expenses of Legal Counsel [Member]
Payments of Stock Issuance Costs	100,000
Underwritten Public Offering [Member] | Clearing Expenses [Member]
Payments of Stock Issuance Costs	$ 10,000
Underwritten Public Offering [Member] | Offering Investor [Member]
Shares Issued, Price Per Share	$ 0.75
Stock Issued During Period, Shares, New Issues	4,000,000
Underwritten Public Offering [Member] | Underwriter [Member]
Shares Issued, Price Per Share	$ 0.69375
Stock Issued During Period, Shares, New Issues	4,000,000
Over-Allotment Option [Member] | Underwriter [Member]
Shares Issued, Price Per Share	$ 0.69375
Stock Issued During Period, Shares, New Issues	1,200,000

Note 13 - Stock Warrants (Detai

Note 13 - Stock Warrants (Details Textual)	Jun. 30, 2019USD ($)$ / sharesshares
Class of Warrant or Right, Outstanding | shares	1,400,000
MT [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2,000
Class of Warrant or Right, Outstanding | shares	300
Minimum [Member]
Warrants and Rights Outstanding, Term	60 days
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.20
Maximum [Member]
Warrants and Rights Outstanding, Term	16 years 73 days
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 50
Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 13.65
Underwriting Agreement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	600,000
Class of Warrant or Right Percent of Common Stock Sold	7.50%
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.9375
Class of Warrant or Right, Exercise Price Percent of Share Price	125.00%
Warrants and Rights Outstanding | $	$ 261,000
Underwriting Agreement Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	88.6
Underwriting Agreement Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	1.8
Underwriting Agreement Warrants [Member] | Measurement Input, Expected Dividend Payment [Member]
Warrants and Rights Outstanding, Measurement Input	0

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Jan. 01, 2018	Dec. 22, 2017	Jun. 30, 2019	Dec. 31, 2018
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	35.00%
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Percentage Reclassified to Income Tax Receivable				50.00%
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax				$ 1,200
Unrecognized Tax Benefits, Ending Balance			$ 0	$ 0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total			130,900
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount			8,700
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total			$ 20,300

Note 15 - Segments (Details Tex

Note 15 - Segments (Details Textual)		3 Months Ended		6 Months Ended
		Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)
Revenues, Total		$ 260,092	$ 542,127	$ 301,716	$ 818,572
Number of Primary Types of Products Sold		2		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 36,726	37,511	$ 73,505	75,498
Selling, General and Administrative Expenses [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total		$ 36,726	$ 37,511	73,505	$ 75,498
Intersegment Eliminations [Member]
Revenues, Total				$ 0
[1]	Depreciation and amortization is reflected in selling, general and administrative expenses ($36,726 and $37,511 for the three-month periods ended June 30, 2019 and 2018, and $73,505 and $75,498 for the six-month periods ended June 30, 2019 and 2018, respectively).

Note 15 - Segments - Segment In

Note 15 - Segments - Segment Information (Details) - USD ($)		3 Months Ended				6 Months Ended
		Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Revenue from contract with customer		$ 16,000		$ 264,000		$ 30,000	$ 265,000
Grant and other revenue		244,199		277,753		282,673	553,403
Revenue		260,092		542,127		301,716	818,572
Cost of revenue		238		35,392		6,364	35,710
Research and development expenses		1,070,642		1,142,718		1,811,225	2,141,674
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,824,874		1,751,888		3,516,611	3,490,273
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	36,726		37,511		73,505	75,498
Loss from operations	[3]	(2,672,388)		(2,425,382)		(5,105,989)	(4,924,583)
Other income (expense)	[4]	(1,590)		(20,719)		7,122	(4,259,480)
Income tax benefit		168		10,929		(708)	10,929
Net loss from continuing operations		(2,673,810)		(2,435,172)		(5,099,575)	(9,173,134)
Income from discontinued operations, net of tax		632		(1,938)		(2,665)	(1,938)
Net income (loss)		(2,673,178)	$ (2,429,061)	(2,394,057)	$ (6,737,962)	(5,102,240)	(9,132,019)
Total assets, net of depreciation and amortization		8,130,395				8,130,395		$ 7,021,527
Capital expenditures				3,165			3,165
Gain on sale of discontinued operations, net of tax				43,053			43,053
UNITED STATES
Total assets, net of depreciation and amortization		8,123,881		8,636,954		8,123,881	8,636,954
Non-US [Member]
Total assets, net of depreciation and amortization		6,514		23,538		6,514	23,538
Royalty [Member]
Revenue from contract with customer		5,940		6,665		9,090	7,460
License [Member]
Revenue from contract with customer		9,953		257,709		9,953	257,709
Diagnostics Segment [Member]
Grant and other revenue		196,630		156,889		232,621	389,325
Revenue		212,523		421,263		251,664	654,494
Cost of revenue		238		35,392		6,364	35,710
Research and development expenses		775,462		913,158		1,516,045	1,698,169
Selling, general and administrative expenses, excluding depreciation and amortization	[1]
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations	[3]	(563,177)		(527,287)		(1,270,745)	(1,079,385)
Other income (expense)	[4]
Income tax benefit		35		2,356		(177)	1,284
Net loss from continuing operations		(563,142)		(524,931)		(1,270,922)	(1,078,101)
Income from discontinued operations, net of tax		632		(1,938)		(2,665)	(1,938)
Net income (loss)		(562,510)		(483,816)		(1,273,587)	(1,036,986)
Capital expenditures
Gain on sale of discontinued operations, net of tax				43,053			43,053
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		220,334		409,769		220,334	409,769
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		6,514		22,147		6,514	22,147
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer		5,940		6,665		9,090	7,460
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer		9,953		257,709		9,953	257,709
Therapeutics Segment [Member]
Grant and other revenue		47,569		120,864		50,052	164,078
Revenue		47,569		120,864		50,052	164,078
Cost of revenue
Research and development expenses		295,180		229,560		295,180	443,505
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	3,062		16,630		14,776	25,237
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations	[3]	(250,673)		(125,326)		(259,904)	(304,664)
Other income (expense)	[4]
Income tax benefit		16		560		(36)	363
Net loss from continuing operations		(250,657)		(124,766)		(259,940)	(304,301)
Income from discontinued operations, net of tax
Net income (loss)		(250,657)		(124,766)		(259,940)	(304,301)
Capital expenditures
Gain on sale of discontinued operations, net of tax
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		11,235		87,751		11,235	87,751
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization
Therapeutics Segment [Member] | Royalty [Member]
Revenue from contract with customer
Therapeutics Segment [Member] | License [Member]
Revenue from contract with customer
Corporate Segment [Member]
Grant and other revenue
Revenue
Cost of revenue
Research and development expenses
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,821,812		1,735,258		3,501,835	3,465,036
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	36,726		37,511		73,505	75,498
Loss from operations	[3]	(1,858,538)		(1,772,769)		(3,575,340)	(3,540,534)
Other income (expense)	[4]	(1,590)		(20,719)		7,122	(4,259,480)
Income tax benefit		117		8,013		(495)	9,282
Net loss from continuing operations		(1,860,011)		(1,785,475)		(3,568,713)	(7,790,732)
Income from discontinued operations, net of tax
Net income (loss)		(1,860,011)		(1,785,475)		(3,568,713)	(7,790,732)
Capital expenditures				3,165			3,165
Gain on sale of discontinued operations, net of tax
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		7,892,312		8,139,434		7,892,312	8,139,434
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization				1,391			1,391
Corporate Segment [Member] | Royalty [Member]
Revenue from contract with customer
Corporate Segment [Member] | License [Member]
Revenue from contract with customer
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Depreciation and amortization is reflected in selling, general and administrative expenses ($36,726 and $37,511 for the three-month periods ended June 30, 2019 and 2018, and $73,505 and $75,498 for the six-month periods ended June 30, 2019 and 2018, respectively).
[3]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4]	Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 16 - Supplemental Disclo_2

Note 16 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Interest Paid, Excluding Capitalized Interest, Operating Activities			$ 6,000	$ 4,000
Stock Issued During Period, Shares, Employee Benefit Plan			8,128	4,734
Stock Issued During Period, Value, Employee Benefit Plan	$ 19,588	$ 35,980	$ 20,000	$ 36,000